Anaplastic Thyroid Cancer: New Hope on the Horizon?
"Discover how new targeted therapies are offering potential breakthroughs in the treatment of anaplastic thyroid cancer, a disease known for its aggressive nature and limited treatment options."
Anaplastic thyroid carcinoma (ATC) is a rare endocrine malignancy that spreads aggressively and is typically resistant to traditional cancer treatments [1-4]. This type of cancer is difficult to treat because it does not respond well to radioiodine, radiotherapy, or chemotherapy. For years, there has been minimal improvement in the survival rates of ATC patients, with a mean survival of approximately 6 months after diagnosis [1-3, 5].
Currently, the most effective approach involves a combination of surgery, chemotherapy (typically doxorubicin and cisplatin), and hyperfractionated accelerated external beam radiotherapy. This multimodal treatment extends median patient survival to about 10 months [6]. However, discovering effective systemic treatments remains critical to managing this aggressive cancer [7].
Emerging research focuses on promising future treatments, including peroxisome proliferator-activated receptor-gamma (PPARγ) agonists, Aurora kinase inhibitors, and tyrosine kinase inhibitors. This article explores these innovative therapies and their potential to transform ATC treatment.
From Genetics to Targeted Therapy
Anaplastic thyroid cancer (ATC) is described as one of the most formidable and aggressive forms of thyroid malignancy. Recent advances in next-generation sequencing have progressively revealed the intricate genetic underpinnings of ATC. This emerging genetic landscape has supported exploration of targeted therapies and reshaped contemporary reviews of molecular diagnosis and multimodal care.
PPARγ Agonists: Can They Redifferentiate Thyroid Cancer Cells?
PPARγ agonists are members of a superfamily of nuclear hormone receptors known for their anti-neoplastic and anti-inflammatory effects [8, 9]. Studies suggest that PPARγ ligands can induce apoptosis (programmed cell death) and prevent the proliferation of various mammalian cells. Excitingly, these ligands also show promise in treating thyroid cancer [10].
- Inducing apoptosis in human papillary thyroid carcinoma cells [10]
- Preventing distant metastasis of BHP18-21 tumors in mice [10]
- Promoting redifferentiation in thyroid cancer cells, potentially reversing the characteristics that make cancer cells aggressive [11-14]
- Downregulating the invasive potential of cancer cells [15]
Targeted Treatment Research
Recent literature examines targeted therapies for dedifferentiated papillary thyroid cancer, including approaches relevant to advanced thyroid malignancies. Earlier work specifically reviewed new targeted therapies for anaplastic thyroid cancer. A study of vemurafenib focused on BRAF(V600E)-mutated ATC, a molecularly defined subgroup of a cancer representing less than 5% of all thyroid carcinomas.
Future Directions in ATC Treatment
While new therapeutic approaches against ATC are under development, more research is needed to identify effective therapies to control and cure this disease. Testing the sensitivity of primary ATC cells from each subject to different drugs could increase the effectiveness of the treatment in the next future. Although there are limitations in selective use of novel compounds, the possibility of testing the sensitivity of primary ATC cells to tyrosine kinase inhibitors could increase the effectiveness of treatments. Additionally, chemosensitivity tests are able to predict in vitro effectiveness in most cases.
Precision and Immunotherapy
ATC has a historical median survival of less than six months, and most patients have advanced disease at diagnosis. Traditional treatments such as surgery, radiotherapy, and chemotherapy have limited therapeutic effects, according to a recent immunotherapy review. That review describes immunotherapy as changing the treatment landscape, while real-world targeted-therapy research evaluates how such treatments perform outside clinical trials.
Molecularly Guided Care
Contemporary reviews emphasize continued work on ATC epidemiology, its molecular landscape, diagnostic strategies, and treatment options. They also identify targeted therapy and multimodal care as important areas of attention. Current approaches include diagnostic evaluation, molecular profiling, and treatment strategies reviewed against current literature and clinical guidelines.
Diagnosis and Multimodal Care
A contemporary review frames ATC care as a problem involving epidemiology, molecular biology, diagnosis, and treatment rather than a single therapeutic decision. Its stated focus includes diagnostic approaches, molecular profiling, targeted therapy, and multimodal care. The review also evaluates these issues against current literature and clinical guidelines.
Evidence Beyond Clinical Trials
Real-world studies are examining targeted therapy and immunotherapy in patients with ATC, but available evidence remains limited and often concerns selected patients. Preliminary phase II ATLEP results suggest clinical activity for lenvatinib plus pembrolizumab in BRAF-wild-type ATC, a group described as having poor prognosis and few effective therapies. Real-world research also identifies molecular testing as difficult because rapid clinical deterioration and long turnaround times can delay results.